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The intestinal mucosa forms the first line of defense against infections mediated by enteric pathogens such as salmonellae. Here
we exploited intestinal “organoids” (iHOs) generated from human induced pluripotent stem cells (hIPSCs) to explore the inter-
action of Salmonella enterica serovar Typhimurium with iHOs. Imaging and RNA sequencing were used to analyze these inter-
actions, and clear changes in transcriptional signatures were detected, including altered patterns of cytokine expression after the
exposure of iHOs to bacteria. S. Typhimuriummicroinjected into the lumen of iHOs was able to invade the epithelial barrier,
with many bacteria residing within Salmonella-containing vacuoles. An S. Typhimurium invAmutant defective in the Salmo-
nella pathogenicity island 1 invasion apparatus was less capable of invading the iHO epithelium. Hence, we provide evidence
that hIPSC-derived organoids are a promising model of the intestinal epithelium for assessing interactions with enteric
pathogens.
Salmonellae are enteric bacterial pathogens that can interactwith, and have the capacity to invade, the intestinal mucosal
surface (1). Globally, salmonellae constitute a huge disease bur-
den, with over 90 million gastroenteritis and 22 million typhoid
cases occurring per year (2). Characterization of the early interac-
tionswith the human epithelial response could provide significant
insight into how salmonellae cause disease (3). Control of infec-
tion is likely achieved through multiple mechanisms, including
cytokine signaling and secretion, inflammasome activation, pro-
duction of reactive oxygen species and antimicrobial peptides, and
phagocyte-mediated microbial killing (4–6).
Human-based in vivo systems are confounded by the technical
challenges of quantifying the interactions between a pathogen and
a mucosal surface, which are likely to be rapid and dynamic (7).
The use of model organisms such as mice to study salmonellae is
commonplace; however, the diseases caused by Salmonella en-
terica serovar Typhimurium differ between mice and humans. In
themouse, S. Typhimurium spreads systemically, and this is char-
acterized by colonization of the liver and spleen (8), whereas S.
Typhimurium causes predominantly localized gastroenteritis in
healthy humans. Therefore, the development of alternative hu-
man in vitromodels for the study of S. Typhimurium is desirable.
Studies on Salmonella interaction with the human intestinal epi-
theliumhave been further hindered by human cell culture systems
(9), which lack the three-dimensional architecture (10) and dif-
ferent cell types that make up the intestinal epithelium. Thus, it
would be desirable to have alternative models in which to study
these important human pathogens.
Intestinal human organoids (iHOs) are a multicellular, hu-
man-specific system that can be used to study host-pathogen in-
teractions at the intestinal interface (11–13). iHOs harbor a mix-
ture of cell types normally present in the intestinal epithelial
barrier in vivo, including goblet cells, Paneth cells, enterocytes,
and enteroendocrine cells (14). iHOs can be derived from human
induced pluripotent stem cells (hIPSCs) (14), which are adult so-
matic cells that have been reprogrammed to pluripotency by the
forced expression of a set of reprogramming factors (15). iHOs
have been exploited to study several different pathogens, includ-
ing Clostridium difficile (16) and rotavirus (12). Characterization
in response to infection of mouse intestinal organoids derived
from adult primary stem cells (17) has also been investigated (11,
13), demonstrating they can secrete functional antimicrobial pep-
tides and that salmonellae disrupt tight junctions and activate in-
flammatory responses.
Here, we investigated the utility of iHOs as a model of S. Ty-
phimurium infection and define the baseline interactions by using
both wild-type and mutant bacteria. We conclude that iHOs pro-
vide a useful system for interrogating some of the complex early
interactions between the enteric pathogen S. Typhimurium and
the intestinal epithelium of the human host.
MATERIALS AND METHODS
Bacterial strains and culture conditions. S. Typhimurium SL1344, a
well-characterized isolate used routinely in laboratory experiments (18),
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was used in these studies. In order to examine iHOs during an attenuated
bacterial infection, we used an S. Typhimurium SL1344 strain defective in
the invA gene of Salmonella pathogenicity island 1 (SPI-1). S. Typhimu-
rium SL1344 carrying an invA deletion was constructed by moving the
invA::Kmr deletion from S. TyphimuriumSL3261 to SL1344 by P22 trans-
duction. invA mutant S. Typhimurium has been described previously
(19). Bacteria were grown in Luria-Bertani broth overnight at 37°C with
shaking. Before infection, bacterial cells were resuspended at 2 107 CFU
ml1 in Dulbecco’s phosphate-buffered saline (Sigma-Aldrich), with 1
106 bacteria added per well of a 24-well plate of organoids. For microin-
jection, bacterial cultures were diluted 1:1 with phenol red (Sigma-Al-
drich).
hIPSC culture. hIPSCs were grown under feeder-free conditions as
previously described (20). To allow adherence of hIPSC colonies, tissue
culture plastic (Corning) was precoated with porcine gelatin (1 g/liter;
Sigma-Aldrich) dissolved in water for embryo transfer (Sigma-Aldrich)
for 30 min, followed by MEF medium consisting of Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen), 10% fetal bovine serum (Biosera),
1% 200 mM L-glutamine (Invitrogen), and 1% penicillin-streptomycin
(10,000 Uml1; Invitrogen). hIPSCs were maintained feeder free at 37°C
and 5% CO2 in chemically defined, serum-free IPSC maintenance me-
dium (CDM-PVA) consisting of 50% DMEM/F-12 (Invitrogen), 50%
Iscove’s modified Dulbecco’s medium (Invitrogen), 5 ml of chemically
defined lipid concentrate (Invitrogen), 450 M monothioglycerol
(Sigma), 7gml1 insulin (Roche), 15gml1 transferrin (Roche), 1mg
ml1 PVA (Sigma), and 10,000 Uml1 penicillin-streptomycin (Invitro-
gen) supplemented with activin A (10 ng ml1; R&D Systems) and basic
fibroblast growth factor (bFGF, 12 ng ml1; R&D Systems). The medium
was changed daily, and hIPSCs were passaged by using a mixture of col-
lagenase and dispase at a ratio of 1:1 every 5 days. The hIPSC line used in
this study was A1ATD-1 (21).
Growth and passaging of intestinal organoids. Before beginning dif-
ferentiation, hIPSCs were passaged and grown for 2 days (days 0 and 1)
under CDM-PVA maintenance conditions (described above). hIPSCs
were differentiated into endoderm, hindgut, and then intestinal or-
ganoids by using a previously published protocol (22). For differentiation
into endoderm, the medium was changed to CDM-PVA supplemented
with 100 ng ml1 activin A (R&D Systems), 100 ng ml1 bFGF (R&D
Systems), 10 ng ml1 bone morphogenetic protein 4 (BMP-4; R&D Sys-
tems), 10 M phosphoinositol 3-kinase inhibitor LY294002 (Promega),
and 3 M CHIR99021 (Stratech Scientific Ltd.), which inhibits GSK3,
resulting inWNTactivation (days 2 and 3, day 3without CHIR99021). To
pattern the definitive endoderm to hindgut, the medium was changed to
RPMI/B-27 medium consisting of RPMI 1640 medium plus GlutaMAX,
10 ml of 50 B27 supplement, 5 ml of nonessential amino acids (Gibco),
and 10,000 U ml1 penicillin-streptomycin (Invitrogen) supplemented
with 100 ng ml1 activin A and 100 ng ml1 bFGF (days 4 and 5, day 5
without bFGF and with activin A at 50 ng ml1). The medium was then
changed to RPMI/B27 supplemented with 3 M CHIR99021 and 3 M
retinoic acid (Sigma) (days 6 to 9). To generate three-dimensional (3D)
intestinal organoids, hindgut tissue was washed with phosphate-buffered
saline (PBS), incubated at 37°C with collagenase, and removed from the
plate via gentle cell scraping. Tissue was manually broken up into smaller
pieces, washed twice by centrifugation, and then resuspended in Matrigel
(growth factor reduced phenol red free; Corning). Sixty-microliter drop-
lets were added to each well of a 24-well plate, incubated for 15 to 20 min
at 37°C, and then covered with 800 l of iHO base growth medium:
Advanced DMEM/F12 (Gibco), 10 ml of 50 B-27 serum-free supple-
ment (Life Technologies), 5 ml of 100N-2 supplement (Life Technolo-
gies), 1% 200 mM L-glutamine, 10,000 U ml1 penicillin-streptomycin,
supplementedwith 500ngml1 R-spondin 1 (R&D), 100 ngml1Noggin
(R&D), 100 ng ml1 epidermal growth factor (EGF; R&D), 3 M
CHIR99021, 10MY-27632 dihydrochloridemonohydrate (Sigma), and
2.5 M prostaglandin E2 (Sigma). The medium was changed every 2 to 3
days. iHOswere passaged every 4 to 6 days by dissolvingMatrigel withCell
Recovery Solution (Corning), washing by centrifugation, manual disrup-
tion of the organoid ultrastructure via pipetting, and resuspension in fresh
Matrigel overlaid with iHO base growth medium.
Stimulation experiments. After at least 6 weeks in culture A1ATD-1
iHOs were challenged with S. Typhimurium SL1344 (1 106 CFUml1)
or left uninfected. Stimulated organoids were incubated for 3 h at 37°C and
5%CO2, and then RNAwas purified with the RNeasy minikit (Qiagen).
Microinjection. After at least 6 weeks in culture, iHOs were prepared
for microinjection 4 days prior to infection by passaging as described
above.Disaggregated iHOswere resuspended in 200l ofMatrigel, plated
into glass bottom Willco Wells microinjection dishes (INTRACEL), and
covered with iHO base growth medium. The Eppendorf TransferMan
NK2-FemtoJet express system was used to inject bacteria into organoids.
All injections were carried out in a chamber at 37°C and 5% CO2. After
injection, organoids were incubated for 3 h at 37°C and 5%CO2 and then
fixed for microscopy. For RNA sequencing (RNA-Seq) analysis, 30 or-
ganoids per microinjection plate were injected with either PBS or S. Ty-
phimurium SL1344 mixed 1:1 with phenol red dye. iHOs were incubated
for 3 h at 37°C and 5% CO2, Matrigel was dissolved with Cell Recovery
Solution (Corning), and phenol red-marked iHOs were isolated. RNA
was then purified with the RNeasy minikit (Qiagen).
RT-qPCR. RNA isolated from whole iHOs before or after injection
was reverse transcribedwith theQuantiTect reverse transcription (RT) kit
(Qiagen) according to the manufacturer’s protocol. All RT-quantitative
PCR (qPCR) experiments were performed with TaqMan gene expression
assays and TaqMan gene expression master mix (Applied Biosystems) on
the Applied Biosystems StepOne real-time PCR system. RT-qPCR data
were analyzed via the comparative CT method with glyceraldehyde
3-phosphate dehydrogenase (GAPDH) as an endogenous control.
RNA-Seq and analysis. RNA was prepared from iHOs microinjected
with S. Typhimurium SL1344 and iHOs microinjected with PBS (as de-
scribed above) for three biological replicates per condition. Multiplexed
mRNA libraries were prepared by using the Illumina TruSeq protocol and
sequenced via paired-end sequencing with the Illumina-C HiSeq 2500
platform. Each lane of Illumina sequence was assessed for quality on the
basis of GC content, average base quality, and adapter contamination.
RNA-Seq reads were aligned with TopHat (23) version 2.0.8 with the
human reference version GRCh37 used for the 1000 Genomes project.
The read counts per gene were generated with featureCounts version
1.4.5-p1. The annotation for featureCounts came from ENSEMBL 75.
Read counts were used to represent gene expression levels. R version 3.1.2
was used to import count data, and the DESeq2 package was used to
normalize the data and detect differentially expressed genes (24). Signifi-
cantly differentially expressed genes were selected with a cutoff false-dis-
covery rate of less than 0.05 and a log change of2.0-fold. Heatmaps and
principal-component analysis (PCA) plots were constructed from rlog-
transformed data with the ggplot2 R library (http://cran.r-project.org
/web/packages/ggplot2/index.html). For the 250 most significantly up-
regulated genes, enriched gene ontology terms were identified by using
InnateDB with the category Biological Processes selected.
Anti-human cytokine/chemokine multiplex bead assays. Triplicate
25-l samples of iHO culture supernatants from unstimulated iHOs and
iHOs stimulated with S. Typhimurium SL1344 by addition to the culture
medium were analyzed for cytokine/chemokine concentrations. Milli-
pore customized anti-human Milliplex magnetic bead kits were used in
accordancewith themanufacturer’s instruction, and amultiplex selection
of the analytes tumor necrosis factor alpha (TNF-), interleukin-6 (IL-6),
and IL-8 was measured. Briefly, 25-l aliquots of supernatants or dilu-
tions of a mixed cytokine standard were captured on anticytokine anti-
body-coated beads overnight. On the following day, after washing with a
96-well plate-formatted magnet, detection reagents were added and al-
lowed to bind to any captured cytokine present on the beads. Following
further washes with the 96-well magnet, data were acquired on a Luminex
FlexMap3D and analyzed with Luminex X-exponent software by extrap-
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olation from the standard-curve dilutions. Results are expressed in pico-
grams per milliliter.
Immunohistochemistry. For immunohistochemical analysis, iHOs
suspended in Matrigel were fixed in 3% paraformaldehyde and 0.125%
glutaraldehyde in PBS for 1 h at room temperature. Theywere then cooled
to 4°C and dehydrated through an ethanol series (25, 50, 70, and 100% for
30 min each), infiltrated with glycol methacrylate (GMA) JB-4 and ben-
zoyl peroxide (JB-4 embedding kit; Sigma-Aldrich), polymerized in gela-
tin capsules at 4°C for 24 to 48 h, and stored at 20°C. One- to 2-m
sections prepared on a Leica UCT ultramicrotome were mounted on
slides precoated with 0.01% (wt/vol) poly-L-lysine hydrobromide. For
immunoperoxidase staining, samples were blocked for 30 min with 0.1%
sodium azide and 100 l of 30% hydrogen peroxide and for 30 min with
RPMI 1640 culturemedium (Invitrogen) with 5% fetal calf serum and 1%
BSA and then washed with TBS buffer (0.6 g of Tris, 8 g of sodium chlo-
ride, 1 liter of distilled H2O [dH2O], 3 to 4ml of 1MHCl to pH 7.6) three
times for 15 min each. Samples were incubated overnight at 4°C with
primary antibodies for mucin 2 (MUC2; ABCAM ab11197), lysozyme
(LYZ;ABCAMab2408), and chromograninA (CHGA;ABCAMab36997)
in TBS buffer at antibody-dependent dilutions (MUC2, 1:200; LYZ, 1:50;
CHGA, 1:50). Bound primary antibodies were detected with the EnVi-
sion System-HRP (AEC) (Dako), and nuclei were visualized by coun-
terstaining withMayer’s hematoxylin. Finally, sections were covered with
GeneTex ClearMount (Sapphire Bioscience) and baked at 80°C for 5min
to set. For immunofluorescence staining for LAMP-1 (ABCAMab24170),
followed by donkey anti-rabbit 647 (ABCAM ab150075) and Salmonella
common structural antigen 1 (CSA-1), fluorescein isothiocyanate-labeled
(Insight Biotechnology Limited 02-91-99) sections were similarly pro-
cessed by omitting the first block and diluting all of the antibodies in PBS
(LAMP-1, 1:50; donkey anti-rabbit 647, 1:100; CSA-1, 1:20). Sections
were mounted in Prolong-Gold with added 4=,6-diamidino-2-phenylin-
dole (DAPI; Invitrogen).
Transmission electron microscopic analysis of infected iHOs. In-
fected organoids were fixed in 2.5% glutaraldehyde and 2% paraformal-
FIG 1 A1ATD-1 hIPSC-derived intestinal organoids show increased expression of genes for markers of adult intestinal tissue. (A) At differentiation day 30, the
expression of adult intestinal markers CHGA (enteroendocrine cells), LYZ (Paneth cells),MUC2 (goblet cells), and VIL1 (enterocytes) was significantly greater
inA1ATD-1 iHOs than inA1ATD-1hIPSCs (P 0.0023,P 8.41 105,P 0.002, andP 4.4 105, respectively). (B) Primerswere validated bymeasuring
the expression of the same markers in RNA isolated from human ileum. (C) Log fold change in the expression of pluripotency markers. The expression of
NANOG and POUF51was significantly lower in A1ATD-1 iHOs on both days 25 (25d) (P 4.64 105 and P 1.99 103) and 55 (55d) (P 3.55 105
and P 3.63 104) than in their A1ATD-1 hIPSC progenitors. Each RT-qPCRwas performed with a TaqMan gene expression assay specific for each gene and
analyzed via the comparative CT method with GAPDH as an endogenous control. *, P	 0.05; **, P	 0.001; ***, P	 0.0001.
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dehyde in 0.1 M sodium cacodylate buffer (1 liter of dH2O, 21.4 g of
sodium cacodylate, 1 g of MgCl2, 0.5 g of CaCl2, adjusted to pH 7.42 with
HCl), postfixed in 1% osmium tetroxide diluted in sodium cacodylate
buffer, dehydrated with an ethanol series, and then embedded with the
Epoxy Embedding Medium kit (Sigma-Aldrich). After embedding, sam-
ples were cured at 65°C for 48 h. Semithin (0.5-m) sections were cut on
a Leica UCT ultramicrotome and stained with toluidine blue on a micro-
scope slide with suitable areas selected for ultrathin 50-nm sectioning.
Ultrathin sections were collected on copper grids and contrasted with
uranyl acetate and lead citrate before viewing on an FEI 120-kV Spirit
BioTWIN transmission electron microscope. Images were taken on an
F4.15 Tietz charge-coupled device camera.
Invasion assays. Microinjection was carried out as described above.
To assess the invasion of iHO epithelial cells by bacteria, we modified the
commonly used gentamicin protection assay (25) for use in iHOs. Forty
iHOs per microinjection dish were injected with either wild-type or invA
mutant S. Typhimurium SL1344. Injected iHOs were incubated for 90
min at 37°C and 5% CO2. iHOs were isolated from Matrigel with Cell
Recovery Solution (Corning), centrifuged, washed once with PBS, sub-
jected to manual disaggregation of the organoid ultrastructure, resus-
pended in iHO base growth medium supplemented with 0.1 mg ml1
gentamicin (Sigma), and incubated at 37°C for 1 h. iHO aggregates were
then centrifuged andwashed oncewith PBS (Sigma). Cells were lysedwith
1% Triton X-100 in PBS. Lysates were serially diluted in PBS, and 20-l
spots were plated onto prewarmed LB plates for CFU counting. Protec-
tion assays were performed with three biological replicates.
Statistical analysis. For statistical comparisons, we used unpaired,
two-tailed t tests done with the Prism 6.0b software (GraphPad).
Nucleotide sequence accession numbers.RNA-Seq data are stored in
the European Genome-Phenome Archive under study accession number
EGAS00001001253. Data will be made available to all researchers upon
request to the Data Access Committee (DAC) for the Wellcome Trust
Sanger Institute, accession number EGAC00001000205. The named per-
son of contact for the DAC for the Wellcome Trust Sanger Institute is
Giselle Kerry (gh2@sanger.ac.uk). The restriction on data access is re-
quired for human donor protection.
RESULTS
IHOs generated fromA1ATD-1 hIPSCs recapitulate features of
the human intestine in vitro. Human intestinal organoids were
generated from A1ATD-1 hIPSCs, which were initially repro-
grammed from dermal fibroblasts (21), in accordance with a pre-
viously published differentiation protocol (22). After 30 days in
culture, there were significantly higher levels of the mRNAs for
MUC2 (mucin 2, goblet cells),VIL1 (Villin 1, enterocytes),CHGA
(chromogranin A, enteroendocrine cells), and LYZ (lysozyme,
Paneth cells) in A1ATD-1 iHOs than in A1ATD-1 hIPSCs (Fig.
1A). These four markers were also highly expressed in control
human ileal tissue (Fig. 1B). In contrast, 25 days after resuspen-
sion inMatrigel and the addition of iHO base growthmedium, we
observed dramatically lower mRNA levels of the pluripotency
markersNANOG and POUF51 in iHOs than in A1ATD-1 hIPSCs
(Fig. 1C).We also observed distinctmorphological changes in our
hIPSC cultures marking the differentiation process to endoderm,
hindgut, and finally iHOs (Fig. 2A). After 1 to 2 weeks inMatrigel,
the iHOs formed spheroid structures of cells enclosing a hollow
lumen, with some crypt-like structures evident in the iHO ultra-
structure. To further dissect the morphology of the iHO wall, we
FIG 2 A1ATD-1 iHOs display amorphology characteristic of the human intestine. (A) Time course showing that directed differentiation of hIPSCs with defined
concentrations of combinations of activin A, FGF, BMP-4, LY294002, and CHIR99021 results in the formation of a definitive endoderm at day 4. After 8 days,
patterning of this definitive endodermwith defined concentrations ofCHIR99021 and retinoic acid results in the formation of hindgut. Placement of this hindgut
into a 3D intestinal culture system consisting of a supporting matrix of Matrigel and medium supplemented with prointestinal proliferation factors R-Spondin
1, Noggin, EGF, CHIR99021, and prostaglandin E2 results in the formation of small spheroids. Sustained maintenance and passaging of these spheroids result
in the formation of established iHO cultures. Images were taken at100magnification. (B) Transmission electronmicrograph of establishedA1ATD-1 iHOwall
demonstrates polarization of epithelial cells with a distinct luminal side (L) andmicrovilli (MV). (C) Transmission electronmicrograph showing the presence of
structures closely resembling tight junctions between cells (ZO, zonula occludens; ZA, zonula adherens; MA, maculae adherens). (D) Immunohistochemistry
with marker-specific antibodies for mucin 2 (goblet cells), lysozyme (Paneth cells), and chromogranin A (enteroendocrine cells) validates the presence of
intestinal secretory cell lineages in the iHO ultrastructure.
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examined iHO cellular structure in more detail by transmission
electron microscopy (Fig. 2B). We were able to visualize a polar-
ized monolayer of epithelial cells, with a clear distinction between
the apical and basal sides, and microvilli present on the apical
surface. Structures resembling tight junctions between epithelial
cells were also evident (Fig. 2C). Finally, we detected the expres-
sion and localization of MUC2, LYZ, and CHGA in iHOs with
marker-specific antibodies and immunohistochemistry within
subsets of cells in the iHOwall (Fig. 2D). The cells expressing these
markers were distributed around the iHO and were not solely
congregated in one region, illustrating that A1ATD-1 iHOs com-
prise enterocytes interspersed with cells harboring genetic signa-
tures typical of Paneth, goblet, and enteroendocrine cells.
Stimulation ofA1ATD-1 iHOswith S. TyphimuriumSL1344
results in altered patterns of gene expression. To probe the
changes in the transcriptome of A1ATD-1 iHOs induced after
infection of iHOs with salmonellae, we microinjected iHOs with
S. Typhimurium SL1344 or PBS as a control and performed a
global RNA-Seq analysis. After differential expression analysis, we
observed 1,448 genes significantly upregulated in iHOs infected
with S. Typhimurium SL1344 (cutoff, log change of2-fold, ad-
justed P value,	0.01) and 577 genes significantly downregulated
(cutoff, log change of	2-fold; adjustedP value,	0.01) compared
to controls. PCA (Fig. 3A) demonstrated clustering of the samples
dependent on treatment, with those samples infected with SL1344
forming a group distinct from the uninjected iHOs, suggesting
different patterns of gene expression in A1ATD-1 iHOs injected
with SL1344. A heat map of the 30 most highly upregulated genes
in iHOs after injection with S. Typhimurium SL1344 consists of a
high proportion of genes associated with response to infection
(Fig. 3B). ILs, essential mediators of the interactions between im-
mune cells and nonhematopoietic cells (26), comprise 6 of the 30
most highly upregulated genes after infection of iHOs with
SL1344. One of the highly expressed ILs was IL-23A, which has
recently been linked with protection of the intestinal barrier
through interaction with the IL-22 signaling pathway (27). IL-20
is also highly expressed after infection with SL1344, and this IL is
associated with epidermal function and psoriasis (28); however,
its role in intestinal infection is undetermined (29). After differ-
ential-expression analysis, we detected significant upregulation of
goblet cell-associated genes such as GCNT3 andMUC2 (30) (log2
change, 1.5022-fold; adjusted P value, 1.68 1046; log2 change,
1.3399-fold; adjusted P value, 0.0059, respectively), suggesting
that multiple cell types that make up the iHO can respond to
SL1344 stimulation. Interestingly, one of the highly upregulated
genes was BIRC3, which is also upregulated in enteroendocrine
cells infected with Chlamydia trachomatis (31). Many genes en-
coding proinflammatory cytokines, including CCL20, IL1B,
IL23A,CSF1,CXCL10, IRAK2,TLR7,TNF,TNIP1,TNFAIP6, and
CCL22, were also significantly upregulated. Factors involved in
the innate immune response, inflammation, cytokine-mediated
signaling, and the response to lipopolysaccharide were all en-
riched in iHOs after infection with S. Typhimurium SL1344
(Fig. 3C; seeData Sets S1 and S2 in the supplementalmaterial). To
validate transcriptional changes in iHOs after infection with S.
Typhimurium SL1344, we carried out further microinjections
with PBS or SL1344 and measured the mRNAs for IL-8, IL1B,
IL23A, TNF, and CXCL2 with quantitative assays (Fig. 3D). The
relative log fold expression of the mRNAs for these five genes
increased significantly in iHOs infected with SL1344, in compar-
isonwith that in organoids infected with PBS. Because of themor-
phology of organoids in culture, it is possible to stimulate them
apically via microinjection or basally through addition to the cul-
ture medium. We produced a global RNA-Seq data set by using
basally stimulated iHOs. To this end, we left clusters of iHOs un-
treated or stimulated themwith S. Typhimurium SL1344 by inde-
pendent addition to the iHO base growthmedium and performed
an RNA-Seq analysis complementary to that carried out for the
microinjected samples. Forty-nine of the 100most highly upregu-
lated geneswere replicated in both data sets (seeData Set S1 and S3
in the supplemental material), and we observed enrichment in
similar pathways after a gene ontology term analysis (seeData Sets
S3 and S4 in the supplemental material). After stimulation with S.
Typhimurium SL1344, we measured the expression of the cyto-
kines TNF-, IL-6, and IL-8 with Luminex cytokine assays to con-
firm their production and secretion by iHOs (Fig. 3E). We de-
tected significantly greater expression of all three cytokines in the
supernatants of SL1344-stimulated iHOs than in unstimulated
iHOs (P 3.34 104, P 6.33 107, and P 3.89 104,
respectively).
Microinjection of iHOs allows direct modeling of S. Typhi-
murium interaction with intestinal cells.Our RNA-Seq analysis
highlighted changes in the global transcriptional landscapes that
are induced after pathogen sensing by the intestinal epithelial cells
that make up the iHO structure. To further model bacterial inva-
sion, we wanted to determine if the iHO system recapitulated
hallmarks of Salmonella invasion such as the formation of the
Salmonella-containing vacuole (SCV). Previous studies have used
organoid dissection to introduce pathogens into the luminal cav-
ity (12); however, we found that a microinjection system was a
robust method (16). We could inject iHOs with a mixture of a
bacterial suspension and phenol red, whichmade it easy to distin-
guish injected and noninjected iHOs in a single culture dish (Fig.
4A). After injection, iHOs retained their inoculum for the 3-h
FIG3 Microinjection of A1ATD-1 iHOswith S. Typhimurium SL1344 results in upregulation of genes associatedwith infection and inflammation. After at least
6 weeks in culture, A1ATD-1 iHOs were microinjected with a mixture of phenol red dye and S. Typhimurium SL1344 with the Eppendorf TransferMan
NK2-FemtoJet express system. iHOs were incubated at 37°C and 5%CO2 for 3 h, phenol red-marked organoids were isolated, and RNAwas prepared. (A) PCA
of RNA-Seq expression data for three biological replicates per condition illustrates distinct differences in gene expression patterns between iHOs stimulated with
SL1344 and unstimulated iHOs. (B) Heat map of the RNA-Seq expression data calculated with DESeq2 for the 30 most significantly upregulated genes after the
addition of SL1344 to A1ATD-1 iHOs. (C) Enriched biological processes upregulated after stimulation of A1ATD-1 iHOs with S. Typhimurium SL1344 (for the
genes associated with each pathway and P values, see Data Set S1 in the supplemental material). (D) RT-qPCR showing that transcripts for the cytokines IL-8,
CXCL2, IL23A, TNF-, and IL1B are significantly upregulated in iHOs injectedwith SL1344 in comparison to those in iHOs injectedwith PBS (P 1.56 109,
P 2.35 109, P 4.21 108, P 1.28 104, and P 6.42 104, respectively). RT-qPCR data were analyzed via the comparative CT method with
GAPDH as an endogenous control. (E) After stimulation of iHOs with S. Typhimurium SL1344, induction of TNF-, IL-6, and IL-8 production was shown to
be significantly upregulatedwith Luminex cytokine assays of supernatants collected from stimulated and unstimulated iHOs (P 3.34 104, P 6.33 107,
P 3.89 104, respectively). Assays were performed with supernatants from three biological replicates.
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incubation time.Weobserved S. Typhimurium in the iHO lumen,
close to the microvilli (Fig. 4B), and also inside the epithelial cells,
residing in structures that resemble SCVs (Fig. 4C).
An S. Typhimurium invA mutant is deficient in invasion of
iHOs. To further confirm the potential of the iHO system in
studying Salmonella infection, we investigated the ability of an S.
Typhimurium SL1344 invA mutant to infect following microin-
jection into the iHO lumen. InvA is an important component of
the SPI-1 invasion system, and this derivative is attenuated in
terms of the ability to enter epithelial monolayers (32). To address
how this mutant behaved in the iHO system, we modified the
gentamicin protection assay (25) regularly used to determine the
percentage of bacterial invasion of epithelial monolayers. We
found that after the microinjection of either wild-type or invA
mutant S. Typhimurium SL1344, we recovered significantly dif-
ferent numbers of CFU after plating epithelial cell lysates (P 
0.0092), with SL1344 invA showing 
30-fold less invasiveness
(Fig. 5A). To confirm our finding, we fixed injected organoids
FIG 4 Microinjection of organoids derived from hIPSCs provides a model of S. Typhimurium SL1344 infection. Overnight cultures of S. Typhimurium SL1344
were diluted 1:1 with phenol red and injected into the lumen (L) of A1ATD-1 iHOs with the Eppendorf TransferMan NK2-FemtoJet express system. (A) iHOs
retained the inoculum for 3 h subsequent to injection. Arrowheads mark the interface between the bacterial inoculum and human cells. (B and C) Transmission
electron micrographs 3 h after injection showing SL1344 populating the lumen of the iHO and residing inside the epithelial cells in SCVs after invasion (arrow)
(B; enlarged in panel C).
FIG 5 S. Typhimurium SL1344 invAmutant is deficient in the invasion of epithelial cells of iHOs. A1ATD-1 iHOs were microinjected with wild-type (WT) or
invAmutant SL1344 and incubated at 37°C and 5%CO2 for 90min. (A) Log numbers of CFU permilliliter recovered from cells of iHOs aftermicroinjection and
modified gentamicin protection assay, showing that WT SL1344 is significantly (
30) more invasive than the invA mutant (P  0.0092). (B) Fluorescence
staining of GMA JB-4- and benzoyl peroxide-fixed sections for CSA-1 (green) and LAMP-1 (red) and an overlay of the two images showing the colocalization
(yellow) of bacteria and host protein after invasion byWT SL1344. invAmutant SL1344 was distinguishable fromWT SL1344 by its lack of induction of LAMP-1
expression.
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after 2 h of incubation and stained them for host protein LAMP-1
and Salmonella CSA-1 (Fig. 5B). In iHOs infected with the S. Ty-
phimurium invA mutant, we detected no salmonellae inside cells
and an almost undetectable positive signal for LAMP-1, suggest-
ing that the invA mutant was not being internalized and the host
cell autophagy pathways were not being significantly triggered. In
contrast, wild-type SL1344 could be found localized within vacu-
oles inside epithelial cells, frequently colocalized with LAMP-1, in
a similar manner to that observed in other in vivo and in vitro
systems (33).
DISCUSSION
We show here that the iHO system is a novel and effective way to
model aspects of the interaction of the enteric pathogen S. Typhi-
murium with the human intestinal epithelium. The iHOs that we
generated from A1ATD-1 hIPSCs display important characteris-
tics of the intestinal epithelium, such as clear polarization of epi-
thelial cells and distinct cell types. We were able to observe large-
scale transcriptional changes in A1ATD-1 iHOs in response to S.
Typhimurium. Dissecting the role of the intestinal epithelium in
defense against S. Typhimurium is important, as these cells are the
entry points for S. Typhimurium into the underlying tissue and
are therefore integral with the innate immune response (1). How-
ever, in whole-mouse infection models, epithelial interactions are
difficult to analyze because of their rarity in the unligated intes-
tine, and traditional immortalized intestinal cell lines lack the ar-
chitecture and the mixture of absorptive and secretory cells that
make up the intestinal epithelium in vivo. The combined action of
different cell types may play a role in influencing the systemic
spread of bacteria such as salmonellae, and the iHO system pro-
vides an opportunity to dissect the roles of these cell types further,
particularly those that have proven difficult to culture in vitro via
traditional cell culture techniques. Furthermore, the use ofmicro-
injection to introduce S. Typhimurium to the apical side of epi-
thelial cells mirrors aspects of S. Typhimurium infection in vivo.
Previous studies have usedmouse primary intestinal organoids
to study various aspects of S. Typhimurium infection (11, 13).
Although these mouse organoids are technically less challenging
and less time-consuming to generate, they lack human genetic
specificity. Therefore, iHOs could find utility for human-re-
stricted pathogens. Data presented here and in previous reports by
other groups (16, 34) suggest that the intestinal organoids derived
from hIPSCs are more small intestine like in structure because of
the presence of Paneth-like cells and the villus-like protrusions
that they develop. S. Typhimurium invades at small intestinal sites
in humans, making the iHOmodel appropriate for studies of this
organism.
As we have shown here, the iHO system can be used to assess
the pathogenesis of different bacterial mutants. iHOs also provide
the opportunity to use information from human and bacterial
genetic studies and rapidly apply that information in this tractable
in vitro setting, allowing the effects of different genetic variants on
the intestinal cellular phenotype to be established (35). For exam-
ple, it is possible to generate hIPSCs, and subsequently iHOs, from
individuals with distinct genetic architectures or those harboring
mutations in known human genes (36). Since both pathogen and
host variations play important roles in the establishment and sub-
sequent development of Salmonella infections, having a system
that enables the application of both could prove to be valuable.
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